RYR1 and neoplasm: The median overall survival among patients with low tumor CcO activity was 14.13 months (95% confidence interval [CI], 12.37 to 18.19), as compared with 6.3 months (95% CI, 4.60 to 6.92) among patients with high tumor CcO activity (P<0.0001 by the log-rank test) (Figure 2C).